Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|EAA172||ECOG-ACRIN||Phase 1/2 Study of Daratumumab, Bortezomib, Dexamethasone with or without Venetoclax in Relapsed/Refractory Multiple Myeloma with Assessment for t(11;14) Status||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1007||SWOG||A Phase III; Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes; Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial RX for Positive Node; Endocrine Responsive Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA4151||ECOG-ACRIN||A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission||Adult CIRB - Late Phase Emphasis||Available to Open|
|AAML1331||COG||A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid: A COG Groupwide Phase III Study||Pediatric CIRB||Available to Open|
|10150||ETCTN||A randomized phase 2 study of bevacizumab and either weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or platinum refractory ovarian cancer||Adult CIRB - Early Phase Emphasis||Available to Open|
|NSABP-B-40||NSABP||A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens||Adult CIRB - Late Phase Emphasis||Available to Open|
|E1609||ECOG||A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma<br>||Adult CIRB - Late Phase Emphasis||Available to Open|
|MAY2016-08-01||CLO-Mayo Clinic||A Pilot Study of MUC1 Vaccine in Current and Former Smokers at High Risk for Lung Cancer||Cancer Prevention and Control CIRB||Available to Open|
|A091304||Alliance||A Phase I /Randomized Phase II Study of MLN0128 vs. Pazopanib In Patients With Locally Advanced/Unresectable And/Or Metastatic Sarcoma||Adult CIRB - Early Phase Emphasis||Available to Open|
|N0147||NCCTG||A Randomized Phase III Trial of Oxaliplatin (OXAL) plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|